---
category: listing
circular_id: 60cb2703b57cabc5
date: '2025-12-31'
description: Listing and trading permission for 16,61,000 equity shares issued on
  preferential basis pursuant to conversion of warrants, effective January 1, 2026.
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={D243424B-B1C3-4092-807E-40C0A57AE015}&noticeno=20251231-15&dt=12/31/2025&icount=15&totcount=29&flag=0
impact: low
impact_ranking: low
importance_ranking: low
justification: Routine listing of preferential allotment shares from warrant conversion
  for a single company with limited market-wide impact
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20251231-15&attachedId=
processing:
  attempts: 1
  content_hash: c4ca9620c0acfde3
  processed_at: '2025-12-31T12:52:27.697943'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-12-31T09:10:42+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={D243424B-B1C3-4092-807E-40C0A57AE015}&noticeno=20251231-15&dt=12/31/2025&icount=15&totcount=29&flag=0
severity: low
source: bse
stocks:
- NOVELIX
tags:
- listing
- equity-shares
- preferential-allotment
- warrant-conversion
- lock-in
title: Listing of New Securities of NOVELIX PHARMACEUTICALS LIMITED
---

## Summary

BSE has listed and permitted trading of 16,61,000 new equity shares of NOVELIX PHARMACEUTICALS LIMITED (Scrip Code: 536565) effective January 1, 2026. These shares were issued at a premium of Rs. 10/- to Promoter and Non-Promoter on preferential basis pursuant to conversion of warrants. The shares rank pari-passu with existing equity shares.

## Key Points

- 16,61,000 equity shares of Rs. 10/- each issued at premium of Rs. 10/-
- Issued to Promoter and Non-Promoter on preferential basis
- Securities issued pursuant to conversion of warrants
- Date of allotment: October 23, 2025
- Issue price: Rs. 20/- per share
- Distinctive numbers: 14480001 to 16141000
- ISIN: INE314I01036
- Shares rank pari-passu with old equity shares

## Regulatory Changes

No regulatory changes introduced.

## Compliance Requirements

Trading members must note the listing and trading permission for these new securities effective January 1, 2026.

## Important Dates

- **Allotment Date**: October 23, 2025
- **Trading Commencement**: January 1, 2026
- **Lock-in Expiry (11,25,000 shares)**: July 31, 2027
- **Lock-in Expiry (5,36,000 shares)**: July 31, 2026

## Lock-in Details

- 11,25,000 shares (Dist. Nos. 14480001-15605000): Locked-in until July 31, 2027
- 5,36,000 shares (Dist. Nos. 15605001-16141000): Locked-in until July 31, 2026

## Impact Assessment

Limited impact confined to NOVELIX PHARMACEUTICALS LIMITED shareholders and traders. The preferential allotment increases total equity base by 16,61,000 shares. Lock-in provisions on all new shares restrict immediate supply, with differential lock-in periods (1.5 years for 5,36,000 shares and 2.5 years for 11,25,000 shares) that will gradually release shares into the market.